• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一名成年转移性前列腺癌患者意外实现长期生存。

Unexpected long-term survival in an adult patient with metastatic prostate cancer.

作者信息

Antonov P, Raycheva G, Popov V

机构信息

Medical University, Plovdiv, Bulgaria.

Clinic of Urology, University Hospital "St. George", Plovdiv, Bulgaria.

出版信息

Urol Case Rep. 2021 Mar 9;37:101634. doi: 10.1016/j.eucr.2021.101634. eCollection 2021 Jul.

DOI:10.1016/j.eucr.2021.101634
PMID:33747795
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7973130/
Abstract

According to statistics, the 5-year overall survival in metastatic prostate cancer is about 21 months. We present a case of a patient with castration-resistant prostate cancer with proven bone lesions 2 years after the onset of the disease and the current survival of over 9 years.

摘要

据统计，转移性前列腺癌的5年总生存率约为21个月。我们报告一例去势抵抗性前列腺癌患者，该患者在疾病发作2年后经证实出现骨转移，目前已存活9年以上。

相似文献

1
Unexpected long-term survival in an adult patient with metastatic prostate cancer.一名成年转移性前列腺癌患者意外实现长期生存。
Urol Case Rep. 2021 Mar 9;37:101634. doi: 10.1016/j.eucr.2021.101634. eCollection 2021 Jul.
2
Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial.卡巴他赛联合考比司他和泼尼松与单独卡巴他赛和泼尼松治疗多西他赛治疗后转移性去势抵抗性前列腺癌患者（AFFINITY）：一项随机、开放标签、国际、3 期临床试验。
Lancet Oncol. 2017 Nov;18(11):1532-1542. doi: 10.1016/S1470-2045(17)30605-8. Epub 2017 Oct 9.
3
Long-term outcomes of definitive external-beam radiotherapy for non-metastatic castration-resistant prostate cancer.局限性外照射治疗去势抵抗性前列腺癌的长期疗效。
Int J Clin Oncol. 2018 Aug;23(4):749-756. doi: 10.1007/s10147-018-1265-8. Epub 2018 Mar 19.
4
Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.醋酸阿比特龙治疗化疗后进展的转移性去势抵抗性前列腺癌患者：多中心、开放标签、早期准入方案试验的最终分析。
Lancet Oncol. 2014 Oct;15(11):1263-8. doi: 10.1016/S1470-2045(14)70417-6. Epub 2014 Sep 18.
5
AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.转移性去势抵抗性前列腺癌患者全血 RNA 中的 AR-V7 转录本与醋酸阿比特龙的反应相关。
J Urol. 2017 Jan;197(1):135-142. doi: 10.1016/j.juro.2016.06.094. Epub 2016 Jul 17.
6
The Effect of Metformin Use during Docetaxel Chemotherapy on Prostate Cancer Specific and Overall Survival of Diabetic Patients with Castration Resistant Prostate Cancer.二甲双胍在多西他赛化疗期间对接受去势抵抗性前列腺癌治疗的糖尿病患者前列腺癌特异性和总生存的影响。
J Urol. 2017 Apr;197(4):1068-1075. doi: 10.1016/j.juro.2016.10.069. Epub 2016 Oct 28.
7
Do the expressions of epithelial-mesenchymal transition proteins, periostin, integrin-α4 and fibronectin correlate with clinico-pathological features and prognosis of metastatic castration-resistant prostate cancer?上皮-间质转化蛋白、骨膜蛋白、整合素-α4和纤连蛋白的表达与转移性去势抵抗性前列腺癌的临床病理特征及预后是否相关？
Exp Biol Med (Maywood). 2017 Dec;242(18):1795-1801. doi: 10.1177/1535370217728499. Epub 2017 Aug 24.
8
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.厄他培隆联合泼尼松治疗化疗初治转移性去势抵抗性前列腺癌（ELM-PC 4）患者：一项双盲、多中心、3 期、随机、安慰剂对照试验。
Lancet Oncol. 2015 Mar;16(3):338-48. doi: 10.1016/S1470-2045(15)70027-6. Epub 2015 Feb 18.
9
Long-term outcomes of combining prostate brachytherapy and metastasis-directed radiotherapy in newly diagnosed oligometastatic prostate cancer: A retrospective cohort study.新诊断寡转移前列腺癌中前列腺近距离放疗与转移灶定向放疗联合应用的长期结果：一项回顾性队列研究。
Prostate. 2019 Apr;79(5):506-514. doi: 10.1002/pros.23757. Epub 2018 Dec 26.
10
Symptoms and Impacts in Metastatic Castration-Resistant Prostate Cancer: Qualitative Findings from Patient and Physician Interviews.转移性去势抵抗性前列腺癌的症状和影响：来自患者和医生访谈的定性发现。
Patient. 2019 Feb;12(1):57-67. doi: 10.1007/s40271-018-0349-x.

引用本文的文献

1
Unleashing novel horizons in advanced prostate cancer treatment: investigating the potential of prostate specific membrane antigen-targeted nanomedicine-based combination therapy.开拓先进前列腺癌治疗的新领域：探索前列腺特异性膜抗原靶向纳米医学联合治疗的潜力。
Front Immunol. 2023 Sep 19;14:1265751. doi: 10.3389/fimmu.2023.1265751. eCollection 2023.
2
The Complexity of Treatments and the Multidisciplinary Team-A Rare Case of Long-Term Progression-Free Survival in Prostate Cancer until Development of Liver and Brain Metastases.治疗的复杂性与多学科团队——前列腺癌长期无进展生存直至出现肝转移和脑转移的罕见病例
J Clin Med. 2023 Aug 27;12(17):5579. doi: 10.3390/jcm12175579.
3

本文引用的文献

1
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.地舒单抗对比唑来膦酸治疗去势抵抗性前列腺癌骨转移患者的随机、双盲研究。
Lancet. 2011 Mar 5;377(9768):813-22. doi: 10.1016/S0140-6736(10)62344-6. Epub 2011 Feb 25.
2
Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.唑来膦酸预防转移性激素难治性前列腺癌患者骨骼并发症的长期疗效。
J Natl Cancer Inst. 2004 Jun 2;96(11):879-82. doi: 10.1093/jnci/djh141.
3
Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients.
Prostate cancer bone metastases biology and clinical management (Review).
前列腺癌骨转移的生物学与临床管理（综述）
Oncol Lett. 2023 Mar 8;25(4):163. doi: 10.3892/ol.2023.13749. eCollection 2023 Apr.
前列腺癌的转移模式：对1589例患者的尸检研究
Hum Pathol. 2000 May;31(5):578-83. doi: 10.1053/hp.2000.6698.